Drug intelligence / Profile preview

OXB-204

Development stage: Discontinued
Lead developer: Oxford BioMedica
Modality: Gene Therapies

Overview

OXB-204 is an investigational **gene therapy** from Oxford BioMedica being developed for **Leber congenital amaurosis type 10**. The program was described as using Oxford BioMedica's proprietary **gene transference technology** to deliver a therapeutic genetic payload intended to address the underlying inherited retinal disease biology in LCA10, a severe congenital retinal disorder that causes profound vision loss from birth or early infancy. Based on the provided information, OXB-204 was in **preclinical development** and listed as available for licensing.

Targets

CEP290 (Centrosomal protein 290)

Beyond the preview

Go deeper on OXB-204.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OXB-204.